Thomas Eric Duncan, the Liberian national who is fighting a severe Ebola infection in Dallas, is getting an experimental treatment, the hospital announced Monday.
The drug is an investigational medication, brincidofovir.
Duncan remains in critical but stable condition, according to Texas Health Presbyterian Hospital Dallas.
Chimerix, Inc., a biopharmaceutical company today announced that brincidofovir has been provided for potential use in patients with Ebola Virus Disease. The company is developing new oral antivirals in areas of high unmet medical need, including Ebola.
The drug was being developed to treat smallpox and the adenovirus, which accounts for about 10 percent of acute respiratory infections in kids and are a frequent cause of diarrhea.
“We are hopeful that brincidofovir may offer a potential treatment for Ebola Virus Disease during this outbreak,” Dr. M. Michelle Berrey, the president and chief executive officer of Chimerix, said in a statement released Monday by the company.
Chimerix is working closely with the Food and Drug Administration to finalize a clinical trial protocol early this week to assess the safety, tolerability, and efficacy of brincidofovir in patients who are confirmed to have an Ebola infection, said a statement released Monday by Chimerix.